NASDAQ:BDSX Biodesix (BDSX) Stock Price, News & Analysis $8.40 -0.48 (-5.41%) Closing price 04:00 PM EasternExtended Trading$8.38 -0.02 (-0.24%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Biodesix Stock (NASDAQ:BDSX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biodesix alerts:Sign Up Key Stats Today's Range$8.36▼$9.0450-Day Range$8.53▼$30.4252-Week Range$5.26▼$31.97Volume168,630 shsAverage Volume484,693 shsMarket Capitalization$93.16 millionP/E RatioN/ADividend YieldN/APrice Target$34.20Consensus RatingModerate Buy Company Overview Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions. Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies. Based in Colorado, Biodesix primarily serves clinicians and patients in the United States through its diagnostic testing services. Its work combines molecular analysis with clinical data to support decision-making across lung cancer care.AI Generated. May Contain Errors. Read More Biodesix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreBDSX MarketRank™: 4.01108557523 of 5 starsBiodesix scored higher than 80% of companies evaluated by MarketBeat, and ranked 169th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingBiodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBiodesix has a consensus price target of $34.20, representing about 307.1% upside from its current price of $8.40.Amount of Analyst CoverageBiodesix has only been the subject of 4 research reports in the past 90 days.Read more about Biodesix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($2.95) to ($1.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 10.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.59% of the float of Biodesix has been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 0.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentBiodesix has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Biodesix this week, compared to 4 articles on an average week.Search Interest2 people have searched for BDSX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.8 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,002,000.00 in company stock, which represents 1.0756% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,002,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders23.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20.96% of the stock of Biodesix is held by institutions.Read more about Biodesix's insider trading history. Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDSX Stock News HeadlinesBIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 57% Share DropNovember 17 at 10:58 PM | tmcnet.comBiodesix Earnings Call Shows Growth Amid Execution ChallengesNovember 17 at 5:57 PM | theglobeandmail.comBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.November 18 at 1:00 AM | Banyan Hill Publishing (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodesix, Inc. - BDSXNovember 17 at 5:35 PM | globenewswire.comBiodesix (BDSX) Stock Fair Value Moves Lower After Q3 Miss And Guidance CutNovember 17 at 1:10 AM | finance.yahoo.comBiodesix (BDSX) Shares Plunge; Johnson Fistel's Colorado Office Initiates Investigation on Behalf of InvestorsNovember 16 at 3:16 PM | globenewswire.comInsider Buying: Biodesix (NASDAQ:BDSX) Director Buys $1,002,000.00 in StockNovember 15 at 11:19 AM | americanbankingnews.comInsider Buying: Biodesix (NASDAQ:BDSX) Director Purchases 100,000 Shares of StockNovember 13, 2026 | insidertrades.comSee More Headlines BDSX Stock Analysis - Frequently Asked Questions How have BDSX shares performed this year? Biodesix's stock was trading at $6.80 at the start of the year. Since then, BDSX stock has increased by 23.5% and is now trading at $8.40. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.00. The company had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27.48 million. Biodesix had a negative net margin of 25.74% and a negative trailing twelve-month return on equity of 442.34%. Read the conference call transcript. When did Biodesix's stock split? Biodesix shares reverse split before market open on Monday, September 15th 2025.The 1-20 reverse split was announced on Thursday, September 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Biodesix IPO? Biodesix (BDSX) raised $72 million in an IPO on Wednesday, October 28th 2020. The company issued 4,000,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. Who are Biodesix's major shareholders? Top institutional shareholders of Biodesix include AIGH Capital Management LLC (6.50%), Soleus Capital Management L.P. (6.02%), Aberdeen Group plc (2.73%) and Marshall Wace LLP (1.67%). Insiders that own company stock include Jack W Schuler, Matthew Strobeck, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Kieran O'kane and Chris Vazquez. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodesix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Palantir Technologies (PLTR), Energy Transfer (ET), Intel (INTC), Micron Technology (MU), NVIDIA (NVDA), SEALSQ (LAES) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 12 days, BDSX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:BDSX CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees334Year Founded2005Price Target and Rating Average Price Target for Biodesix$34.20 High Price Target$40.00 Low Price Target$30.00 Potential Upside/Downside+307.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.26 million Net Margins-25.74% Pretax Margin-25.74% Return on Equity-442.34% Return on Assets-29.16% Debt Debt-to-Equity Ratio5.43 Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual Sales$88.50 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book10.77Miscellaneous Outstanding Shares11,090,000Free Float8,516,000Market Cap$93.16 million OptionableNo Data Beta0.65 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BDSX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.